BIOMARIN PHARMACEUTICAL INC·4

Mar 17, 8:50 PM ET

Guyer Charles Greg 4

Research Summary

AI-generated summary

Updated

BioMarin (BMRN) CTO Greg Guyer Receives RSUs, Sells 9,109 Shares

What Happened

  • Greg Guyer, EVP & Chief Technical Officer at BioMarin (BMRN), disposed of 9,109 shares on 2026-03-13 at $58.51 each for total proceeds of $532,968. The Form 4 lists this as a payment to cover an exercise price or tax liability (code F).
  • On 2026-03-16 Guyer was granted equity awards: 14,990 restricted stock units (RSUs) and 35,680 shares reported as an acquired derivative award (both shown with $0 purchase price on the filing).

Key Details

  • Filing date: 2026-03-17. Period of report shown as 2026-03-13; transactions reported on 2026-03-13 and 2026-03-16.
  • Sale: 9,109 shares @ $58.51 = $532,968 (disposed to satisfy tax/option obligations; code F).
  • Grants: 14,990 RSUs (price N/A) and 35,680 derivative award (price $0).
  • Post-transaction holdings: Not specified in the provided excerpt of the filing.
  • Footnotes: F1 confirms the 14,990 are RSUs granted 3/16/2026; F2 corrects prior direct holdings by one share; F3 describes vesting for the option/derivative grant — 12/48th vests on 3/16/2027 and then 1/48th monthly thereafter.
  • No explicit late-filing indicator shown in the provided data; filing was submitted 3/17/2026.

Context

  • The 9,109-share disposition was recorded as a tax/exercise payment (common when RSUs vest or options are exercised) rather than an open-market investment sale; this is typically administrative rather than a directional bet on the stock.
  • The awards granted (RSUs and a derivative/option-like award with a multiyear vesting schedule) represent compensation and future equity interest that will vest over time; such grants are standard executive compensation and do not by themselves signal immediate buying or selling intent.